List of chemotherapy regimens: Difference between revisions

Jump to navigation Jump to search
m (→‎Overview: addition of citation)
Line 89: Line 89:
| Fludarabine, mitoxantrone (Novantrone), dexamethasone
| Fludarabine, mitoxantrone (Novantrone), dexamethasone
| Recurrent or refractory indolent [[non-Hodgkin lymphoma]]
| Recurrent or refractory indolent [[non-Hodgkin lymphoma]]
|-
| '''FOLFIRI''' <ref name="pmid10744089">{{cite journal |author=Douillard JY, Cunningham D, Roth AD, ''et al.'' |title=Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial |journal=Lancet |volume=355 |issue=9209 |pages=1041–7 |year=2000 |month=March |pmid=10744089 |doi= |url=}}</ref>
| Leucovorin, infusional fluorouracil, irinotecan
| Metastatic [[colorectal cancer]]
|-
|-
| '''[[FOLFOX]]'''
| '''[[FOLFOX]]'''

Revision as of 21:00, 16 July 2010

WikiDoc Resources for List of chemotherapy regimens

Articles

Most recent articles on List of chemotherapy regimens

Most cited articles on List of chemotherapy regimens

Review articles on List of chemotherapy regimens

Articles on List of chemotherapy regimens in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on List of chemotherapy regimens

Images of List of chemotherapy regimens

Photos of List of chemotherapy regimens

Podcasts & MP3s on List of chemotherapy regimens

Videos on List of chemotherapy regimens

Evidence Based Medicine

Cochrane Collaboration on List of chemotherapy regimens

Bandolier on List of chemotherapy regimens

TRIP on List of chemotherapy regimens

Clinical Trials

Ongoing Trials on List of chemotherapy regimens at Clinical Trials.gov

Trial results on List of chemotherapy regimens

Clinical Trials on List of chemotherapy regimens at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on List of chemotherapy regimens

NICE Guidance on List of chemotherapy regimens

NHS PRODIGY Guidance

FDA on List of chemotherapy regimens

CDC on List of chemotherapy regimens

Books

Books on List of chemotherapy regimens

News

List of chemotherapy regimens in the news

Be alerted to news on List of chemotherapy regimens

News trends on List of chemotherapy regimens

Commentary

Blogs on List of chemotherapy regimens

Definitions

Definitions of List of chemotherapy regimens

Patient Resources / Community

Patient resources on List of chemotherapy regimens

Discussion groups on List of chemotherapy regimens

Patient Handouts on List of chemotherapy regimens

Directions to Hospitals Treating List of chemotherapy regimens

Risk calculators and risk factors for List of chemotherapy regimens

Healthcare Provider Resources

Symptoms of List of chemotherapy regimens

Causes & Risk Factors for List of chemotherapy regimens

Diagnostic studies for List of chemotherapy regimens

Treatment of List of chemotherapy regimens

Continuing Medical Education (CME)

CME Programs on List of chemotherapy regimens

International

List of chemotherapy regimens en Espanol

List of chemotherapy regimens en Francais

Business

List of chemotherapy regimens in the Marketplace

Patents on List of chemotherapy regimens

Experimental / Informatics

List of terms related to List of chemotherapy regimens

Associate Editor-in-Chief: Ross Bonander

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Acronyms often identify the individual agents used in combination chemotherapy regimens. Unfortunately, the letters used are not consistent across regimens, and in some cases (for example, "BEACOPP") the same letter is used to represent two different treatments. Because of this, there is not a naming standard for chemotherapy regimens, and this page merely represents commonly used conventions.

The term "Induction regimens" refers to a chemotherapy regimen which is used for the initial treatment of a disease.

Name Components Example of uses, and other notes
ABVD [1] Adriamycin, bleomycin, vinblastine, dacarbazine Hodgkin's lymphoma
ABVE-PC [2] Doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide Pediatric Hodgkin's lymphoma
AC Adriamycin/Doxorubicin, Cyclophosphamide Breast cancer
ADOC [3] Doxorubicin, cisplatin, vincristine, cyclophosphamide Thymic carcinoma
BEACOPP [4] Bleomycin, etoposide, Adriamycin (doxorubicin), cyclophosphamide, Oncovin (vincristine), procarbazine, prednisone Hodgkin's lymphoma
BEP Bleomycin, etoposide, platinum (cisplatin) Testicular cancer, germ cell tumors
CAF Cyclophosphamide, Adriamycin/Doxorubicin, 5-FU/Fluorouracil Breast cancer
CAV Cyclophosphamide, Adriamycin/Doxorubicin, Vincristine Lung cancer
CHOP Cyclophosphamide, doxorubicin (hydroxydoxorubicin), vincristine (Oncovin), prednisone Non-Hodgkin lymphoma
CHOP-R CHOP + rituximab B cell non-Hodgkin lymphoma
COP or CVP Cyclophosphamide, vincristine (Oncovin), and prednisone Non-Hodgkin lymphoma in patients with history of cardiovascular disease
CMF Cyclophosphamide, Methotrexate, and 5-Fluorouracil Breast Cancer
COPP Cyclophosphamide, Oncovin (vincristine), procarbazine and prednisone Non-Hodgkin lymphoma
DA-EPOCH [5] Dose-adjusted Etopiside, prednisone, vincristine (Oncovin), Cyclophosphamide and doxorubicin Newly diagnosed, aggressive non-Hodgkin lymphoma
DHAP [6] Dexamethasone, cytarabine (high-dose ARA-C), cisplatin Recurrent or refractory non-Hodgkin lymphoma
EC Epirubicin, Cyclophosphamide Breast cancer
ECF Epirubicin, cisplatin, fluorouracil Gastric cancer and oesophageal cancer
ESHAP Etopiside, methylprednisolone (Solu-medrol), cytarabine (ARA-C), cisplatin Relapsed or refractory non-Hodgkin lymphoma
FN-D [7] Fludarabine, mitoxantrone (Novantrone), dexamethasone Recurrent or refractory indolent non-Hodgkin lymphoma
FOLFIRI [8] Leucovorin, infusional fluorouracil, irinotecan Metastatic colorectal cancer
FOLFOX Fluorouracil, leucovorin (folinic acid), and oxaliplatin Colorectal cancer
HYPER-CVAD [9] Hyperfractionated cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin), dexamethasone (Decadron) Burkitt's lymphoma
ICE [10]' Ifosfamide, carboplatin, etopiside Relapsed or primary refractory non-Hodgkin lymphoma
ICE-R ICE + rituximab Relapsed or primary refractory non-Hodgkin lymphoma
IFL [11] Irinotecan, bolus fluorouracil and leucovorin Metastatic colorectal cancer
m-BACOD Methotrexate, bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone (Decadron) Non-Hodgkin lymphoma
MACOP-B [12] Methotrexate, leucovorin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), prednisone, bleomycin Non-Hodgkin lymphoma
Mini-BEAM [13] Carmustine (BCNU), etopiside, cytarabine (Ara-C), melphalan Hodgkin's lymphoma (Salvage therapy, pre-transplant)
MOPP Mechlorethamine, vincristine (oncovin), procarbazine, prednisone Hodgkin's lymphoma
MVAC [14] Methotrexate, vinblastine, doxorubicin, cisplatin Bladder cancer
NABTT [15] Methotrexate, calcium leucovorin; methotrexate, calcium leucovorin; methotrexate, calcium leucovorin Primary CNS lymphoma
PCV [16] Procarbazine, lomustine (CCNU), vincristine Brain tumors
ProMACE-MOPP Methotrexate, doxorubicin (Adriamycin), cyclophosphamide, etoposide + MOPP Non-Hodgkin lymphoma
ProMACE-CytaBOM Prednisone, doxorubicin (adriamycin), cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine (Oncovin), methotrexate, leucovorin Non-Hodgkin lymphoma
R-FCM Rituximab, fludarabine, cyclophosphamide, mitoxantrone B cell non-Hodgkin lymphoma
RTOG 93-10 [17] Methotrexate, Leucovorin, vincristine, procarbazine, methotrexate, Leucovorin Primary CNS lymphoma
Stanford V [18] Doxorubicin (Adriamycin), mechlorethamine, bleomycin, vinblastine, vincristine (Oncovin), etoposide (VP-16), prednisone Hodgkin's lymphoma
TAC [19] Docetaxel, doxorubicin, cyclophosphamide Metastatic breast cancer
Thal/Dex Thalidomide, dexamethasone Multiple myeloma
Treanda + Rituxan Bendamustine, Rituximab Indolent and mantle cell lymphomas
VAD Vincristine, Adriamycin (doxorubicin), dexamethasone Multiple myeloma
VCAP-AMP-VECP [20] Vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP)--doxorubicin, ranimustine, and prednisone (AMP)-- vindesine, etoposide, carboplatin, and prednisone (VECP) Adult T-cell leukemia-lymphoma (ATLL)
VeIP [21] Vinblastine, ifosfamide, cisplatin Testicular cancer
VIP [22] Etopiside, ifosfamide, cisplatin Testicular cancer
  1. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975). "Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP". Cancer. 36 (1): 252–9. PMID 54209. Unknown parameter |month= ignored (help)
  2. Schwartz CL, Constine LS, Villaluna D; et al. (2009). "A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425". Blood. 114 (10): 2051–9. doi:10.1182/blood-2008-10-184143. PMID 19584400. Unknown parameter |month= ignored (help)
  3. Berruti A, Borasio P, Gerbino A; et al. (1999). "Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience". Br. J. Cancer. 81 (5): 841–5. doi:10.1038/sj.bjc.6690773. PMC 2374302. PMID 10555755. Unknown parameter |month= ignored (help)
  4. Diehl V, Franklin J, Hasenclever D; et al. (1998). "BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group". J. Clin. Oncol. 16 (12): 3810–21. PMID 9850026. Unknown parameter |month= ignored (help)
  5. Wilson WH, Grossbard ML, Pittaluga S; et al. (2002). "Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy". Blood. 99 (8): 2685–93. PMID 11929754. Unknown parameter |month= ignored (help)
  6. Velasquez WS, Cabanillas F, Salvador P; et al. (1988). "Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)". Blood. 71 (1): 117–22. PMID 3334893. Unknown parameter |month= ignored (help)
  7. McLaughlin P, Hagemeister FB, Romaguera JE; et al. (1996). "Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma". J. Clin. Oncol. 14 (4): 1262–8. PMID 8648382. Unknown parameter |month= ignored (help)
  8. Douillard JY, Cunningham D, Roth AD; et al. (2000). "Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial". Lancet. 355 (9209): 1041–7. PMID 10744089. Unknown parameter |month= ignored (help)
  9. Thomas DA, Cortes J, O'Brien S; et al. (1999). "Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia". J. Clin. Oncol. 17 (8): 2461–70. PMID 10561310. Unknown parameter |month= ignored (help)
  10. Moskowitz CH, Bertino JR, Glassman JR; et al. (1999). "Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma". J. Clin. Oncol. 17 (12): 3776–85. PMID 10577849. Unknown parameter |month= ignored (help)
  11. Saltz LB, Cox JV, Blanke C; et al. (2000). "Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group". N. Engl. J. Med. 343 (13): 905–14. PMID 11006366. Unknown parameter |month= ignored (help)
  12. Klimo P, Connors JM (1985). "MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma". Ann. Intern. Med. 102 (5): 596–602. PMID 2580468. Unknown parameter |month= ignored (help)
  13. Colwill R, Crump M, Couture F; et al. (1995). "Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation". J. Clin. Oncol. 13 (2): 396–402. PMID 7844600. Unknown parameter |month= ignored (help)
  14. von der Maase H, Hansen SW, Roberts JT; et al. (2000). "Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study". J. Clin. Oncol. 18 (17): 3068–77. Unknown parameter |month= ignored (help)
  15. Herrlinger U, Schabet M, Brugger W; et al. (2002). "German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma". Ann. Neurol. 51 (2): 247–52. PMID 11835382. Unknown parameter |month= ignored (help)
  16. Levin VA, Edwards MS, Wright DC; et al. (1980). "Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors". Cancer Treat Rep. 64 (2–3): 237–44. PMID 7407756.
  17. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002). "Combination chemotherapy and radiotherapy for primary central nervous system". J. Clin. Oncol. 20 (24): 4643–8. PMID 12488408. Text " lymphoma: Radiation Therapy Oncology Group Study 93-10 " ignored (help); Unknown parameter |month= ignored (help)
  18. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ (1995). "Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report". J. Clin. Oncol. 13 (5): 1080–8. PMID 7537796. Unknown parameter |month= ignored (help)
  19. Nabholtz JM, Mackey JR, Smylie M; et al. (2001). "Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer". J. Clin. Oncol. 19 (2): 314–21. PMID 11208821. Unknown parameter |month= ignored (help)
  20. Tsukasaki K, Utsunomiya A, Fukuda H; et al. (2007). "VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801". J. Clin. Oncol. 25 (34): 5458–64. doi:10.1200/JCO.2007.11.9958. PMID 17968021. Unknown parameter |month= ignored (help)
  21. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998). "Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor". J. Clin. Oncol. 16 (7): 2500–4. PMID 9667270. Unknown parameter |month= ignored (help)
  22. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998). "Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study". J. Clin. Oncol. 16 (4): 1287–93. PMID 9552027. Unknown parameter |month= ignored (help)

See also

External links

Template:Chemotherapeutic Agents Template:SIB

Template:WS